Reportlinker Adds Prostate Cancer: Vaccines and Therapeutic Antibodies, 2010

NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer: Vaccines and Therapeutic Antibodies, 2010

http://www.reportlinker.com/p0253289/Prostate-Cancer-Vaccines-and-Therapeutic-Antibodies-2010.html

The prostate cancer immunotherapy pipeline is showing rapid development. Currently, there are 30 candidates in the pipeline (16 vaccines and 14 therapeutic antibodies), and one prostate cancer vaccine (Provenge®) has recently been approved by the FDA.

First-line treatments for prostate cancer are largely based on anti-androgen drugs, or pituitary down-regulators. Other treatments include surgery, radiotherapy and chemotherapy. Resistance is commonly seen in the case of androgen-targeting drugs.  Other therapies such as surgery and radiotherapy may be effective, but present increased risk. These treatment limitations have prompted efforts to develop safer, targeted therapies.

In April 2010, Dendreon Inc. received FDA approval for its vaccine, Provenge® – an autologous cellular immunotherapy developed for metastatic prostate cancer. This vaccine is based on the use of patients' own peripheral blood mononuclear cells, following prior treatment with a Prostate Acid Phosphatase/Granulocyte-Macrophage Colony-Stimulating Factor (PAP/GM-CSF) fusion protein. PAP is a commonly expressed prostate cancer antigen.

The development of new candidate vaccines and therapeutic antibodies to target prostate cancer, is showing rapid progress. There are 30 candidates in the pipeline (16 prostate cancer vaccines and 14 prostate cancer-targeting antibodies), and one FDA-approved prostate cancer vaccine (Provenge®). Of these candidates, 19 are at Phases II and III (nine vaccines and 10 antibodies) and eight are at Phase I.

These vaccines and antibodies are targeting more than fifteen different prostate cancer-associated antigens or other prostate cancer-associated proteins, and are being taken forward by 25 companies: 20 small and medium sized enterprises, and five multinational pharmaceutical companies.

This report provides a comprehensive update on the prostate cancer immunotherapy pipeline, and includes summary pre-clinical and clinical findings (pre-clinical to Phase III) on the candidate vaccines and antibodies presented.

This report provides:

  • a comprehensive update on the prostate cancer vaccine and therapeutic antibody pipeline;
  • summary pre-clinical and clinical findings (where published) for all candidate vaccines and antibodies presented;
  • descriptions of vaccine-targeting mechanisms (antigens and targets); and
  • details of development companies.

Report Contents

Due to the nature of this report, some details (name of candidate vaccine or therapeutic antibody, together with their respective antigen or target) in this report contents page, have been omitted. However, sample data are provided in the case of candidates at Phase II, Phase I and preclinical/research stages. 

Executive Summary

Chapter 1 Background p.7

1. Prostate Cancer

1.1 Statistics

1.2 Diagnosis

1.3 Staging

1.4 Current Treatments

1.5 This Report

Chapter 2 Prostate Cancer Immunotherapy Strategies p.12

2.1 Vaccines & Antibodies

Chapter 3 Approved Vaccine p.18

3.1 Dendreon (sipuleucel-T, Provenge®, vaccine, PAP+, Approved)

Chapter 4 Phase III Vaccines and Antibodies p.23

4.1 Summary

4.2 Phase III Vaccines & Antibodies

4.3 [Company] (name, antibody, antigen/target, Phase III)

4.4 [Company] (name, vaccine, antigen/target, Phase III)

4.5 [Company] (name, antibody, antigen/target, Phase III)      

Chapter 5 Phase II Vaccines and Antibodies p.28

5.1 Summary

5.2 Phase II Vaccines & Antibodies

5.3 [Company] (name, antibody, antigen/target, Phase II)       

5.4 [Company] (name, vaccine, antigen/target, Phase II)    

5.5 (Bellicum Pharmaceuticals, BPX-101, vaccine, iCD40+, Phase II)

5.6 [Company] (name, vaccine, antigen/target, Phase II)

5.7 [Company] (name, antibody, antigen/target, Phase II)

5.8 [Company] (name, vaccine, antigen/target, Phase II)

5.9 [Company] (name, vaccine, antigen/target, Phase II)

5.10 [Company] (name, vaccine, antigen/target, Phase II)

5.11 [Company] (name, antibody, antigen/target, Phase II)

5.12 [Company] (name, vaccine, antigen/target, Phase II)

5.13 [Company] (name, antibody, antigen/target, Phase II)

5.14 [Company] (name, antibody, antigen/target, Phase II)

5.15 [Company] (name, antibody, antigen/target, Phase II)

5.16 [Company] (name, radio antibody, antigen/target,  Phase II)

5.17 [Company] (name, antibody, antigen/target, Phase II)

5.18 [Company] (name, vaccine, antigen/target, Phase II)

Chapter 6 Phase I Vaccines and Antibodies p.57

6.1 Summary

6.2 Phase I Vaccines & Antibodies

6.3 [Company] (name, vaccine, antigen/target, Phase I)

6.4 [Company] (name, antigen/target, Phase I)

6.5 [Company] (name, vaccine, antigen/target, Phase I)

6.6 Mannkind Corporation (MKC1106-PP, PRAME+ and PSMA+, Phase I)

6.7 [Company] (name, vaccine, antigen/target, Phase I)

6.8 [Company] (name, vaccine, antigen/target, Phase I)

6.9 [Company] (name, antibody, antigen/target, Phase I)

6.10 [Company] (name, antibody, antigen/target, Phase I)

Chapter 7 Preclinical & Research Vaccines and Antibodies p.75

7.1 Summary

7.2 Preclinical & Research Vaccines & Antibodies

7.3 Advaxis (ADXS31-142, vaccine, PSA+, Preclinical)

7.4 [Company] (name, vaccine, antigen/target, Preclinical)

7.5 [Company] (name, antibody, antigen/target, Preclinical)

Chapter 8 Discussion p.80

8.1 Discussion

+ = antigen or antibody target

List of Tables

Table 4.1 Prostate cancer vaccines and therapeutic antibodies at Phase III (company, name, type (antibody or vaccine), antigen/target).

Table 5.1 Prostate cancer vaccines and therapeutic antibodies at Phase II (company, name, type (antibody or vaccine), antigen/target).

Table 6.1 Prostate cancer vaccines and therapeutic antibodies at Phase I (company, name, type (antibody or vaccine), antigen/target).

Table 7.1 Prostate cancer vaccines and therapeutic antibodies in preclinical research or research (company, name, type (antibody or vaccine), antigen/target).

Table 8.1 Prostate cancer vaccines and therapeutic antibodies at Preclinical/Research, Phase I. Phase II, Phase III and Approved (company, name, type (antibody or vaccine), antigen/target).

List of Figures

Figure 8.1 Prostate cancer vaccines and therapeutic antibodies at Preclinical/Research, Phase I, Phase II, Phase III and Approved

To order this report:

Pathology Industry: Prostate Cancer: Vaccines and Therapeutic Antibodies, 2010

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.